Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03832114
Other study ID # CLNP023X2202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 20, 2019
Est. completion date April 23, 2021

Study information

Verified date January 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date April 23, 2021
Est. primary completion date April 23, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for Cohort A and B: - Written informed consent must be obtained before any assessment is performed - Male and female patients between the ages of 18 to 65 (inclusive) at screening - C3G patients wit proteinuria - Able to communicate well with the investigator, to understand and comply with the requirements of the study - At screening and baseline visits, patients must weigh at least 35 kg - Supine vital signs should be within the following ranges : oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm . Inclusion Criteria for Cohort A: - Estimated GFR (using the CKD-EPI formula) or measured GFR =30 mL/min per 1.73 m2 for patients on a maximum recommended or maximum tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) - UPCR = 100 mg/mmol (equivalent to = 1 g/24h total urinary protein excretion) - Prior to entry, all patients must have been on supportive care including a maximally tolerated dose of ACEi or ARB for at least 30 days. Inclusion Criteria for Cohort B: - No histological/laboratory/clinical signs of allorejection - If applicable, induction treatment after allotransplantation needs to be completed >30 days before inclusion. - Transplantation of a kidney allograft >90 days before inclusion - Patients need to be on a stable dose of immunosuppressive regimen prior to inclusion. Any approved treatments are allowed for this purpose. Exclusion Criteria for Cohort A and B: - Use of other investigational drugs at the time of enrollment, or within 5 half-lives of randomization, or within 30 days, whichever is longer; or longer if required by local regulations - A history of clinically significant ECG abnormalities, - Known family history or known presence of long QT syndrome or Torsades de Pointes - Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study - Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. - Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of investigational drug. - History of immunodeficiency diseases, or a positive HIV test result. - Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV). - Patients who cannot receive vaccinations against N. meningitidis, S. pneumoniae, or H. influenzae

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LNP023
Increasing doses of LNP023 up to 200 mg.

Locations

Country Name City State
France Novartis Investigative Site Montpellier
France Novartis Investigative Site Paris
Germany Novartis Investigative Site Essen
Italy Novartis Investigative Site Ranica BG
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Madrid
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Newcastle Upon Tyne
United States Novartis Investigative Site Iowa City Iowa

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  France,  Germany,  Italy,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) Change in proteinuria assessed by ratio to baseline of UPCR derived from 24h urine collection Week 12
Primary Cohort B: Change From Baseline in C3 Deposit Histopathological changes in kidney biopsies as assessed by change from baseline in C3 Deposit Score (based on immunofluorescence microscopy) Week 12
Secondary Change From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR) Ratio to baseline UPCR derived from 24 hour urine collection Week 12: Day 84
Secondary Change From Baseline in Urine Protein (UP) Excretion Ratio to baseline UP excretion derived from 24 hour urine collection Week 12: Day 84
Secondary Change From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion Ratio to baseline UACR excretion derived from 24 hour urine collection Week 12: Day 84
Secondary Change From Baseline Change in Urinary Albumin (UA) Excretion Ratio to baseline UA excretion derived from 24 hour urine collection Week 12: Day 84
Secondary Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Effect of LNP023 on estimated glomerular filtration rate (eGFR) Day 84
Secondary Change From Baseline in Serum Creatinine The effect of LNP023 on renal function - serum creatinine Week 12: Day 84
Secondary Change From Baseline in Creatinine Clearance The effect of LNP023 on renal function - creatinine clearance Week 12: Day 84
Secondary Number of Patients With Hematuria The effect of LNP023 on renal function - hematuria Week 12: Day 84
Secondary Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void Ratio to baseline of UPCR reduction derived from total cumulative urinary excretion first morning void Week 9: Day 64
Secondary Change From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void UACR reduction derived from total cumulative urinary excretion first morning void Week 9: Day 64
Secondary Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC) The area under the plasma concentration-time curve calculated from time zero to the last quantifiable concentration point (hr*ng/mL) Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Secondary Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC) The area under the plasma concentration-time curve calculated to the end of the dosing interval (hr*ng/mL) Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Secondary Observed Maximum Concentration After Drug Administration (Cmax) The observed maximum plasma concentration (ng/mL) Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Secondary Observed Minimum Concentration After Drug Administration (Ctrough) The concentration that is just prior to the beginning of, or at the end, of a dosing interval (ng/mL) Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Secondary Time to Reach the Maximum Plasma Concentration (Tmax) The time to reach peak or maximum concentration (hr) Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Secondary Summary of Change From Baseline Complement C3 Biomarker in Serum To assess the effect of LNP023 on alternative complement pathway hyperactivity. Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
Secondary Ratio to Baseline Summary of Plasma Bb To assess the relationship between LNP023 dose and pharmacodynamic biomarker levels of blood Bb Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
See also
  Status Clinical Trial Phase
Completed NCT00001457 - Lamivudine for Chronic Hepatitis B Phase 2
Recruiting NCT05505955 - Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency Phase 1
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Active, not recruiting NCT05174221 - A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Phase 1
Completed NCT00426348 - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Phase 4
Recruiting NCT04662723 - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Phase 4
Completed NCT02700516 - Recurrent Glomerulonephritis After Renal Transplantation N/A
Recruiting NCT00862693 - Calcitriol in the Treatment of Immunoglobulin A Nephropathy Phase 4
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT00004990 - Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis Phase 2
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Terminated NCT04387448 - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Phase 2
Terminated NCT04950114 - An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases Phase 2
Completed NCT00437463 - Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor Phase 3
Terminated NCT02523768 - Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Phase 4
Completed NCT00106561 - Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney Phase 2/Phase 3
Completed NCT04733040 - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) Phase 2
Completed NCT00001676 - Cyclophosphamide and Fludarabine to Treat Lupus Nephritis Phase 1
Recruiting NCT02063100 - Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis Phase 4
Completed NCT01093157 - A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Phase 1/Phase 2